1. IDEALS AND OBJECTIVES
The Government of Japan established the Hideyo Noguchi Africa Prize in July 2006 in memory of Dr. Hideyo Noguchi whose contribution to medical advancement and self-sacrificing activities in Africa remain a paragon of professionalism. Mindful of the ominous human suffering persisting in Africa, the region facing the most serious health challenge on the globe, the Prize aims to honour individuals with outstanding achievements in the fields of medical research and medical services to combat infectious and other diseases in Africa, thus contributing to the health and welfare of the African people and of all humankind.
2. WHO ARE ELIGIBLE ?
- The Prize is aimed at individuals and organizations active in the field of medical research and medical services in Africa.
- In the field of medical services in particular, it is required that their activities take place in Africa or that the activities concerned be based in Africa contributing to improvements in the health and welfare of people living in Africa.
- No distinction will be made according to nationality, age or gender.
- The Prize will be limited to people still living or organizations currently active.
3. HOW OFTEN ?
This Prize will be awarded every five years to coincide with the Tokyo International Conference on African Development (TICAD). The first award was presented at the award ceremony on 28th May 2008, the first day of TICAD IV.
4. VALUE OF THE AWARD
The Prize consists of a citation, a medal and an honorarium of 100 million yen.
5. PROCESS OF SELECTION
The selection process comprises two stages, namely: (a) recommendation of a maximum of three candidates by two sub-Committees administratively supported by the Japan Society for the Promotion of Science (JSPS) in respect of "medical research", and the Regional Office for Africa of the World Health Organization (AFRO) in respect of "medical services"; and (b) finalization of the candidates by the Hideyo Noguchi Africa Prize Committee to be referred to the Prime Minister for final decision.